

September 28, 1970

Dr. Wilma Harrison
Geigy Pharmaceuticals
Ardsley, New York

Dear Wilma,

I have read the two EEG studies of GP 41299 by Kales and Dement with great interest. I have read of Kales' sleep studies for a few years, but this is my first opportunity to directly compare my techniques with his. Dement has not previously been identified with new drug studies.

Both studies suggest that GP 41299 enhances REM activity - a finding interpreted by Dement as almost unique (see pg. 23). Kales failed to elicit effects on REM at 50 or 100 mg doses. Both Dement and Kales, for reasons that are not specified, suggest studies in insomniacs. This recommendation does not seem to be based on the study data, but on information which is not clearly stated.

Most striking, in both studies, is the absence of statistical sophistication in defining the drug induced EEG changes. I was surprised by the small sample size, and the impressionistic nature of the summary statements.

I cannot determine the relation of this data to the alert EEG profile of GP 41299 as we defined it, but I am most grateful for the opportunity to examine these studies and to attempt such a correlation. I find nothing in these data to be inconsistent with our observations or conclusions, and would continue with our suggestions.

Again, my thanks for the change to read these two reports, and my best regards.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:kt